Trial Profile
An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Apr 2022 Planned End Date changed from 31 Jan 2023 to 9 Jun 2025.
- 20 Apr 2022 Planned primary completion date changed from 31 Jan 2023 to 9 Jan 2025.
- 08 Dec 2021 This trial has been completed in Japan, according to Japan Pharmaceutical Information Center - Clinical Trials Information record.